Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2α

Journal of Immunology

Volumn 161, Issue 10, 1998, Pages 5164-5170

  Rifkin, Ian R ^a   Channavajhala, Padma L ^a   Kiefer, Heather L B ^a   Carmack, Adrienne J ^a   Landesman Bollag, Esther ^a   Beaudette, Britte C ^a   Jersky, Brian ^b   Salant, David J ^a   Ju, Shyr Te ^a   Marshak Rothstein, Ann ^a   Seldin, David C ^a,c  

^a BOSTON UNIVERSITY   (United States)

^b SONOMA STATE UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; ENZYME ACTIVITY; GENE MUTATION; GROWTH REGULATION; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD45; ANTIGENS, CD8; AUTOIMMUNE DISEASES; CASEIN KINASE II; GENE EXPRESSION REGULATION; HETEROZYGOTE; HOMOZYGOTE; LYMPHATIC DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; SPLENOMEGALY; T-LYMPHOCYTE SUBSETS; TRANSGENES;

EID: 0032533823     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Cohen, P., and R. Eisenberg. 1991. lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
2. Theofilopoulos, A., and F. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
3. Izui, S., V. Kelley, K. Masuda, H. Yoshida, J. Roths, and E. Murphy. 1984. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133:277.
4. Kelley, V., and J. Roths. 1985. Interaction of mutant lpr gene with background strain influences renal disease. Clin. Immunol. Immunopathol. 37:220.
5. Watanabe-Fukunaga, R., C. Brannan, N. Copeland, N. Jenkins, and S. Nagata. 1992. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
6. Takahashi, T., M. Tanaka, C. Brannan, N. Jenkins, N. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76:969.
7. 2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195.
8. Ju, S.-T., D. Panka, H. Cui, R. Ettinger, M. El-Khatib, D. Sherr, B. Stanger, and A. Marshak-Rothstein. 1995. FasL interactions required for programmed cell death after T cell activation. Nature 373:444.
9. Brunner, T., R. Mogil, D. LaFace, N. Yoo, A. Mahboubi, F. Echeverri, S. Martin, W. Force, D. Lynch, C. Ware, and D. Green. 1995. Cell-autonomous Fas (CD95)/ Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 373:441.
10. Dhein, J., H. Walczak, C. Baumler, K.-M. Debatin, and P. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1(Fas/CD95). Nature 373:438.
11. Singer, G., and A. Abbas. 1994. The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
12. Drappa, J., A. Vaishnaw, K. Sullivan, J.-L. Chu, and K. Elkon. 1996. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1643.
13. Fisher, G., F. Rosenberg, S. Straus, J. Dale, L. Middelton, A. Lin, W. Strober, M. Lenardo, and J. Puck. 1995. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935.
14. Rieux-Laucat, F., F. Le Deist, C. Hivroz, I. Roberts, K. Debatin, A. Fischer, and J. de Villartay. 1995. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347.
15. Sneller, M., J. Wang, J. Dale, W. Strober, L. Middelton, Y. Choi, T. Fleisher, M. Lim, E. Jaffe, J. Puck, M. Lenardo, and S. Straus. 1997. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 89:1341.
16. Landowski, T., N. Qu, I. Buyuksal, J. Painter, and W. Dalton 1997. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90:4266.
17. Fishman, P. 1994. Autoimmunity and cancer. Isr. J. Med. Sci. 30:15.
18. Osterland C. 1996. Monoclonal gammopathies antigen driven in autoimmune disease. Clin. Exp. Rheumatol. 14(Suppl. 14):S37.
19. Anaya, J., H. McGuff, P. Banks, and N. Talal. 1996. Clinicopathological factors relating malignant lymphoma with Sjogren's syndrome. Semin. Arthritis Rheum. 25:337.
20. Valesini, G., R. Priori, D. Bavoillot, J. Osborn, M. Danieli, N. D. Papa, R. Gerli, M. Pietrogrande, M. Sabbadini, F. Silvestris, and L. Valsecchi. 1997. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J. Rheumatol. 24:2376.
21. Strasser, A., S. Whittingham, D. Vaux, M. Bath, J. Adams, S. Cory, and A. Harris. 1991. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA 88:8661.
22. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. J. Montgomery, J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215.
23. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4:1.
24. Harvey, M., M. J. McArthur, C. J. Montgomery, A. Bradley, and L. A. Donehower. 1993. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7:938.
25. Landesman-Bollag, E., P. L. Channavajhala, R. D. Cardiff, and D. C. Seldin. 1998. p53 Deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene. 16:2965.
26. Allende, J. E., and C. C. Allende. 1995. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and puzzling regulation [Review]. FASEB J. 9:313.
27. Faust, R. A., M. Gapany, P. Tristani, A. Davis. G. L. Adams, and K. Ahmed. 1996. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett. 101:31.
28. Yenice, S., A. T. Davis, S. A. Goueli, A. Akdas, C. Limas, and K. Ahmed. 1994. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 24:11.
29. Daya-Makin, M., J. S. Sanghera, T. L. Mogentale, M. Lipp, J. Parchomchuk, J. C. Hogg, and S. L. Pelech. 1994. Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res 54:2262.
30. Gapany, M., R. A. Faust, S. Tawfic, A. Davis. G. L. Adams, and K. Ahmed. 1995. Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol. Med. 1:659.
31. Munstermann, U., G. Fritz, G. Seitz, Y. P. Lu, H. R. Schneider, and O. G. Issinger. 1990. Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur. J. Biochem. 189:251.
32. ole-MoiYoi, O. K., W. C. Brown, K. P. Iams, A. Nayer, T. Tsukamoto, and M. D. Macklin. 1993. Evidence for the induction of casein kinase II in bovine lymphocytes transformed by the intracellular protozoan parasite Theileria parva. EMBO J. 12:1621.
33. Seldin, D. C., and P. Leder. 1995. Casein kinase II α transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267:894.
34. Kelliher, M. A., D. C. Seldin, and P. Leder. 1996. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα EMBO J. 15:5160.
35. + T cells reactivated with superantigen are both more sensitive to FasL-mediated killing and express a higher level of FasL. Cell. Immunol. 179:153.
36. Siu, G., S. P. Clark, Y. Yoshikai, M. Malissen, Y. Yanagi, E. Strauss, T. W. Mak, and L. Hood. 1984. The human T cell antigen receptor is encoded by variable, diversity, and joining gene segments that rearrange to generate a complete V gene. Cell 37:393.
37. Perkins, D., J. Michaelson, and A. Marshak-Rothstein. 1987. The lpr gene is associated with resistance to engraftment by lymphoid but not erythroid stem cells from normal mice. J. Immunol. 138:466.
38. Singer, P. A., and A. N. Theofilopoulos. 1990. T-cell receptor Vβ repertoire expression in murine models of SLE. Immunol. Rev. 188:103.
39. Eisenberg, R., J. Winfield, and P. Cohen. 1982. Subclass restriction of anti-Sm antibodies in MRL mice. J. Immunol. 129:2146.
40. Clynes, R., C. Dumitru, and J. Ravetch. 1998. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 279:1052.
41. Bullard, D., P. King, M. Hicks, B. Dupont, A. Beaudet, and K. Elkon. 1997. Intercellular adhesion molecule-1 deficiency protects MRL/Mpj-Fas lpr mice from early lethality. J. Immunol. 159:2058.
42. Reap, E., N. Felix, P. Wolthusen, B. Kotzin, P. Cohen, and R. Eisenberg. 1995. bcl-2 transgenic lpr mice show profound enhancement of lymphadenopathy. J. Immunol. 155:5455.
43. Moroy, T., A. Grzeschiczek, S. Petzold, and K. Hartmann. 1993. Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/ lpr mice. Proc. Natl. Acad. Sci. USA 90:10734.
44. Zhou, T., C. K. Edwards, 3rd, P. Yang, Z. Wang, H. Bluethmann, and J. D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156:2661.
45. Zornig, M., A. Grzeschiczek, M. B. Kowalski, K. U. Hartmann, and T. Moroy. 1995. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E μ L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10:2397.
46. Andrews, B., R. Eisenberg, A. Theofilopoulos, S. Izui, C. Wilson, P. McConahey, E. Murphy, J. Roths, and F. Dixon. 1978. Spontaneous murine lupus-like syndromes. J. Exp. Med. 148:1198.